Eli Lilly and Co. announced it has secured FDA approval to market Alimta as a first-line treatment in combination with cisplatin, a chemotherapy drug, for advanced and metastatic nonsmall-cell lung cancer. The agency has cleared Alimta for the treatment of a rare type of lung cancer primarily caused by asbestos and as a second-line treatment for lung cancer patients who have received chemotherapy.

Related Summaries